Tag : PROSTATE CANCER

Patients with high-risk localized prostate cancer (HR LPC) are at significant risk of developing systemic or local recurrence as well as symptoms and/or death from the disease. While there is a range of treatment options available, including radical prostatectomy (RP), radiation therapy with or without androgen deprivation therapy (ADT), and chemotherapy, there is currently no consensus on the optimal treatment for these patients. The role and benefits of using neoadjuvant or adjuvant ADT in HR LPC patients are also inconclusive, especially among Asia-Pacific patients treated with RP and perioperative hormonal therapy (HT). As such, this retrospective observational study was performed to describe the real-world clinical characteristics and treatment patterns of HR LRPC patients in Japan, South Korea and Taiwan.

Prostate cancer remains a leading cause of cancer-related deaths in men.1,2 Despite early detection and treatment, the mortality burden of early prostate cancer by 75 years of age remains high.

In 2019, prostate cancer (PC) was ranked the third most frequently diagnosed cancer among men in Hong Kong. Though genetic testing has not been previously considered a routine approach of PC patient care, recent sequencing studies revealed that about 11.8% of metastatic PC (mPC) patients carried in